Cullen/Frost Bankers, Inc. Tricida, Inc. Transaction History

Cullen/Frost Bankers, Inc.

  • $7.23 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 07, 2022
SELL
$4.19 - $9.56 $142 - $325
-34 Closed
0 $0
Q2 2021

Aug 05, 2021
BUY
$3.95 - $5.41 $134 - $183
34 New
34 $0

Others Institutions Holding TCDA

# of Institutions
4
Shares Held
30K
Call Options Held
124K
Put Options Held
46.5K
View Full List

About Tricida, Inc.

TCDA Quotes by TradingView
  • Ticker TCDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,668,900
  • Market Cap $557K
  • Description
  • Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...
More about TCDA
Track This Portfolio

Track Cullen/Frost Bankers, Inc. Portfolio

Follow Cullen/Frost Bankers, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cullen/Frost Bankers, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cullen/Frost Bankers, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email